Up-Regulation Of Microrna-93 Predicates Advanced Clinicopathological Features And Serves As An Unfavorable Risk Factor For Survival Of Patients With Non-Small Cell Lung Cancer

MiRNA-93-5p (miR-93) has been reported to be differentially regulated in a variety of neoplastic diseases. However, there are few studies of clinical relevance of miR-93 on non-small cell lung cancer (NSCLC), particularly its relationship with prognosis in patients with NSCLC. In this study, we investigated the expression levels of Micro-93 (miR-93) in non-small cell lung cancer tissues and adjacent non-tumor tissues and the relationship with clinical significance. Expression levels of miR-93 in 104 pairs of NSCLC and adjacent non-tumor tissues were measured by quantitative real-time PCR (qRT-PCR). All the patients were divided into 2 groups according to the different expression levels of miR-93. Then, clinic-pathological features and expression levels of miR-93 were compared. In order to explore its prognostic value, overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method, and multivariate analysis was estimated using the Cox-proportional hazards regression model. It was observed that miR-93 expression level was significant higher in NSCLC tissues compared with adjacent non-tumor tissues (P<0.001), and miR-93 was correlated with lymph nodes metastasis and clinical stage, while was not correlated with age, gender, tumor size, smoking, etc. Univariate Kaplan-Meier analysis revealed a significant correlation between high miR-93 expression level and poor progression-free survival (P=0.020) and overall survival (P=0.008). Furthermore, a multivariate Cox regression analysis revealed high miR-93 expression (HR=5.93, 95% CI=1.25-11.38) and clinical stage (HR=4.90, 95% CI=0.29-15.73) were predictor of poor prognosis of the patients with NSCLC. We conclude that up-regulation of MiR-93 is correlated with worse clinic-pathological features, indicating it serves as an independent marker for poor prognosis in patients with Non-small cell lung cancer.